Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Stock Chart & Stats
$3.93
$0.18(4.59%)
At close: 4:00 PM EST
$3.93
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.41 - $7.37
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.12M
Market Cap
$343.19M
Enterprise Value$213.40M
Total Cash (Recent Filing)$236.14M
Total Debt (Recent Filing)$21.94M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Nov 06, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding77,910,240
10 Day Avg. Volume876,136
30 Day Avg. Volume1,115,463
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue68.31
Enterprise Value/Gross Profit-128.79
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$15.10Price Target Upside284.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory StrategyManagement's new strategy involves multiple meetings with the FDA to ensure thorough discussions on critical topics, aiming for a clearer pathway to accelerated approval.
Safety ProfileThe company reported a strong safety profile with zero drug-induced liver injury and detection of lower AST/ALT levels, indicating muscle recovery.
Therapeutic PotentialSGT-003's therapeutic potential for Duchenne muscular dystrophy remains strong and competitive, solidifying its status as a best-in-class treatment.
Bears Say
Micro-Dystrophin ExpressionThree of the ten evaluable patients showed suboptimal micro-dystrophin expression, which lowered the overall average.
Outliers Impacting DataThe drop in microdystrophin expression from 110% to 58% was impacted by three outliers, although management aims to optimize future results by amending the protocol.
Regulatory Timeline DelayThe decision to push the expected FDA meeting to a later date was made to build a more robust data package, indicating a delay in the regulatory timeline.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.41 and its highest was $7.37 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $343.19M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Nov 06, 2025 which is yesterday.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Aug 12, 2025. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.077.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.43.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 77,910,240 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -0.658%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
Solid Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
400.92% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$15.10 (284.22% Upside)
$15.10 (284.22% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.17%
12-Months-Change
Fundamentals
Return on Equity
-86.83%
Trailing 12-Months
Asset Growth
29.31%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. is a biotechnology company dedicated to developing transformative treatments for patients with Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration and weakness. The company's leading program focuses on gene therapy and aims to address the underlying genetic cause of DMD. Headquartered in Charlestown, Massachusetts, Solid Biosciences is at the forefront of pioneering therapies in the field of rare genetic diseases.
SLDB Stock 12 Month Forecast
Average Price Target
$15.10
▲(284.22% Upside)
Technical Analysis
Autolus Therapeutics
―
Korro Bio
―
ADC Therapeutics
―
Opthea Limited Sponsored ADR
―
Monte Rosa Therapeutics
―
Ownership Overview
34.17% Insiders
9.38% Mutual Funds
0.01% Other Institutional Investors
49.19% Public Companies and Individual Investors
Options Prices
Currently, No data available
---